The US Food and Drug Administration (FDA) approved aducanumab, an anti-amyloid immunotherapy, for the treatment of Alzheimer’s disease (AD) in 2021. The approval was based on the evidence that aducanumab reduces amyloid plaques in the brain. In this case, amyloid load was used as a surrogate endpoint, meaning that the reduction in amyloid plaques was thought to reflect clinical benefit, however is not itself a measure of clinical benefit. Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, provides his perspective on this choice, particularly emphasizing that amyloid load in the brain is not directly related to cognitive symptoms, therefore it should not necessarily be used to predict clinical benefit. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
